4.6 Article

The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response

Journal

CANCERS
Volume 12, Issue 3, Pages -

Publisher

MDPI
DOI: 10.3390/cancers12030742

Keywords

melanoma; PTEN; immune evasion

Categories

Funding

  1. Swedish Research Council (Vetenskapsradet)
  2. Swedish Cancer Society
  3. Berta Kamprad Foundation
  4. Crafoord foundation
  5. European Union [641458]
  6. Stefan Paulsson foundation
  7. Mats Paulsson foundation
  8. governmental funding for healthcare research (ALF)
  9. Marie Curie Actions (MSCA) [641458] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

Checkpoint blockade therapies have changed the clinical management of metastatic melanoma patients considerably, showing survival benefits. Despite the clinical success, not all patients respond to treatment or they develop resistance. Although there are several treatment predictive biomarkers, understanding therapy resistance and the mechanisms of tumor immune evasion is crucial to increase the frequency of patients benefiting from treatment. The PTEN gene is thought to promote immune evasion and is frequently mutated in cancer and melanoma. Another feature of melanoma tumors that may affect the capacity of escaping T-cell recognition is melanoma cell dedifferentiation characterized by decreased expression of the microphtalmia-associated transcription factor (MITF) gene. In this study, we have explored the role of PTEN in prognosis, therapy response, and immune escape in the context of MITF expression using immunostaining and genomic data from a large cohort of metastatic melanoma. We confirmed in our cohort that PTEN alterations promote immune evasion highlighted by decreased frequency of T-cell infiltration in such tumors, resulting in a worse patient survival. More importantly, our results suggest that dedifferentiated PTEN negative melanoma tumors have poor patient outcome, no T-cell infiltration, and transcriptional properties rendering them resistant to targeted- and immuno-therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available